Silvercrest Asset Management’s NovoCure NVCR Stock Holding History

Silvercrest Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.1M	Buy	928,740 +143,935	+18%	+$2.18M	0.09%	282
2026 Q1	$8.55M	Buy	784,805 +77,196	+11%	+$964K	0.06%	335
2025 Q4	$9.15M	Buy	707,609 +1,534	+0.2%	+$19.7K	0.06%	332
2025 Q3	$9.12M	Buy	706,075 +165,778	+31%	+$2.21M	0.06%	333
2025 Q2	$9.62M	Buy	540,297 +82,269	+18%	+$1.43M	0.06%	322
2025 Q1	$8.16M	Buy	458,028 +109,721	+32%	+$2.49M	0.06%	330
2024 Q4	$10.4M	Sell	348,307 -147,804	-30%	-$3.13M	0.07%	292
2024 Q3	$7.75M	Buy	496,111 +110,701	+29%	+$2.01M	0.05%	307
2024 Q2	$6.6M	Buy	+385,410	New	+$6.78M	0.05%	352
2021 Q1	–	Sell	-1,384	Closed	-$239K	–	865
2020 Q4	$239K	Sell	1,384 -1,787	-56%	-$245K	﹤0.01%	751
2020 Q3	$353K	Buy	+3,171	New	+$254K	﹤0.01%	648

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Silvercrest Asset Management's NVCR Position: Q2 2026 in Review

Silvercrest Asset Management increased its NovoCure (NVCR) stake by 18% in Q2 2026, buying an estimated $2.18M and bringing the position to 928,740 shares worth $14.1M. The position accounts for 0.09% of the portfolio, ranked #282.

Silvercrest Asset Management first reported a position in NVCR in Q3 2020 and has held it in 11 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Silvercrest Asset Management held 928,740 shares of NovoCure worth $14.1M as of Q2 2026.
Silvercrest Asset Management bought 143,935 NovoCure shares in Q2 2026, an estimated $2.18M.
NovoCure made up 0.09% of Silvercrest Asset Management's portfolio in Q2 2026, its #282 holding.
Silvercrest Asset Management first reported a position in NovoCure in Q3 2020 and has held it in 11 quarters since.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.